NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis

Monte Rosa Therapeutics, Inc. (GLUE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

GLUE

$13.84

−$0.54 (−3.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GLUE with… →

GLUE Key Statistics

As of Sep 4, 2026
Trading
Open
$14.12
Previous Close
$14.38
Day's Range
13.79–14.31
52-Week Range
4.79–25.77
Volume
804.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.50
Valuation
Market Cap
$1.18B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
41.10
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.68
Financials (FY)
Revenue (FY)
$123.67M+63.54%
Net Income (FY)
−$38.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
85.31M
1-Year Return
+181.87%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.44M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GLUE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−11.73%
2025+125.94%
2024+22.83%
2023−25.76%
2022−62.73%
2021 (partial year)−3.59%

As of September 4, 2026.

GLUE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$123.67M−$38.63M−31.2%
2024$75.62M−$72.70M−96.1%
2023$0.00−$135.35M—
2022$0.00−$108.50M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$123.67M—−$54.21M−$38.63M−31.2%
2024$75.62M—−$81.11M−$72.70M−96.1%
2023$0.00—−$143.31M−$135.35M—
2022$0.00—−$112.38M−$108.50M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GLUE Valuation vs Biotechnology Median

Median of 656 stocks
MetricGLUEBiotechnology medianvs median
P/S ratio41.1015.26169% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Monte Rosa Therapeutics, Inc. (GLUE) carries a market capitalisation of $1.18B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 173.

The 52-week range on file runs from $4.79 to $25.77. GLUE last closed at $13.84 on September 4, 2026. That is −$0.54 (−3.76%) against the previous close. The latest close sits 188.94% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $123.67M. That is +63.54% against the prior fiscal year, when revenue was $75.62M. The same year closed with a net loss of $38.63M. The reported profit margin is 0%. Trailing earnings per share are −1.68.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $123.67M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 41.1 times revenue. On price-to-sales that is 169.28% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.5. Daily returns over the trailing 5 years annualize to a volatility of 101.23%. The trailing one-year price return is +181.87%. Measured over 5 years, that is −19.99% a year compounded.

Growth & Income

The record shows no dividend for GLUE.

Across the complete calendar years on file, 2025 returned +125.94% and 2022 returned −62.73%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −11.73% year to date.

Peer Comparison

Monte Rosa Therapeutics, Inc. (GLUE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Monte Rosa Therapeutics, Inc. GLUE $1.18B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Monte Rosa Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Visit website →